MedTrace Logo

Abraxane in Treatment of Metastatic Breast Cancer

NCT02555696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2017-02-23

No results posted yet for this study

Summary

This observational project is collecting tolerability, safety and efficacy data with the routine use of Abraxane in the treatment of metastatic breast cancer. Additionally data on the dosage of Abraxane and general data on the disease and the health status of the patient will be collected.

Conditions

Interventions

DRUG

nab-paclitaxel

nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Guenter Voraberger · Celgene

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2016-02-28
Completion
2016-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555696 on ClinicalTrials.gov